Biomedical Engineering Reference
In-Depth Information
12. Harlow E, Lane D. Antibodies: A Laboratory Manual, Cold Spring Harbor Press, Cold
Spring Harbor, NY, 1988.
13. Joelsson D et al. Optimizing ELISAs for precision and robustness using laboratory
automation and statistical design of experiments. J. Immunol. Methods 2008.337
(1):35-41.
14. Anderson MJ, Whitcomb PJ. DOE Simplified: Practical Tools
for Effective
Experimentation, Productivity Press, 2000.
15. Anderson MJ, Kraber SL. Eight keys to successful DOE. Quality Digest 1999 (July).
16. Anderson M, Anderson H. Applying DOE to microwave popcorn. PI Quality 1993
(July/August);3.
17. EMEA. Guideline on Immunogenicity Assessment of Biotechnology-Derived
Therapeutic Proteins, Committee for Medicinal Products for Human Use (CHMP), 2007.
18. FDA. Bioanalytical Method Validation, CDER, U.S. Department of Health and Human
Services, 2001.
19. Koren E et al. Recommendations on risk-based strategies for detection and
characterization of antibodies against biotechnology products. J. Immunol. Methods
2008.333(1-2):1-9.
20. Mire-Sluis, AR et al. Recommendations for the design and optimization of immunoassays
used in the detection of host antibodies against biotechnology products. J. Immunol.
Methods 2004.289(1-2):1-16.
21. Shankar, G et al. Recommendations for the validation of immunoassays used for detection
of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008;48
(5):1267-1281.
22. ICH. Text on validation of analytical procedures, I.C.F. Harmonization, 1995.
23. ICH. Validation of analytical procedures: methodology, I.C.F. Harmonization, 1995.
24. Manshouri T et al. Circulating CD20 is detectable in the plasma of patients with chronic
lymphocytic leukemia and is of prognostic significance. Blood 2003;101(7):2507-2513.
25. Albitar M et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic
leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004;101
(5):999-1008.
26. Kaplan IV, Levinson SS. When is a heterophile antibody not a heterophile antibody?When
it is an antibody against a specific immunogen clinical chemistry. Clin. Chem. 1999;45:3.
27. Weber TH, Kapyaho KI, Tanner P. Endogenous interference in immunoassays in clinical
chemistry. A review. Scand. J. Clin. Lab. Investig. 1990;50 (201 Suppl.):77-82.
28. Wang J et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing,
prevention and treatment. Nat. Biotechnol. 2008;26(8):901-908.
Search WWH ::




Custom Search